These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

165 related articles for article (PubMed ID: 35429141)

  • 1. Mubritinib enhanced the inhibiting function of cisplatin in lung cancer by interfering with mitochondrial function.
    Dong J; Zhu D; Chen M; Wang T; Gao Y; Liu W
    Thorac Cancer; 2022 May; 13(10):1513-1524. PubMed ID: 35429141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Silencing long non-coding RNA ROR improves sensitivity of non-small-cell lung cancer to cisplatin resistance by inhibiting PI3K/Akt/mTOR signaling pathway.
    Shi H; Pu J; Zhou XL; Ning YY; Bai C
    Tumour Biol; 2017 May; 39(5):1010428317697568. PubMed ID: 28459375
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antitumor effects of flavokawain-B flavonoid in gemcitabine-resistant lung cancer cells are mediated via mitochondrial-mediated apoptosis, ROS production, cell migration and cell invasion inhibition and blocking of PI3K/AKT Signaling pathway.
    Hua R; Pei Y; Gu H; Sun Y; He Y
    J BUON; 2020; 25(1):262-267. PubMed ID: 32277640
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Investigation on the mechanism of the combination of eremias multiocellata and cisplatin in reducing chemoresistance of gastric cancer based on
    Cheng FE; Li Z; Bai X; Jing Y; Zhang J; Shi X; Li T; Li W
    Aging (Albany NY); 2024 Feb; 16(4):3386-3403. PubMed ID: 38345573
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Fuzheng Jiedu Decoction Induces Apoptosis and Enhances Cisplatin Efficacy in Ovarian Cancer Cells
    Yang H; Li H; Lu S; Shan S; Guo Y
    Biomed Res Int; 2022; 2022():5739909. PubMed ID: 35281608
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Co-treatment with BEZ235 enhances chemosensitivity of A549/DDP cells to cisplatin via inhibition of PI3K/Akt/mTOR signaling and downregulation of ERCC1 expression.
    Xia A; Li H; Li R; Lu L; Wu X
    Oncol Rep; 2018 Oct; 40(4):2353-2362. PubMed ID: 30066933
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Polydatin, a potential NOX5 agonist, synergistically enhances antitumor activity of cisplatin by stimulating oxidative stress in non‑small cell lung cancer.
    Wu S; Zhao Q; Liu S; Kuang J; Zhang J; Onga A; Shen Y; Wang J; Sui H; Ni L; Ye Y; Tu X; Le HB; Zheng Y; Cui R; Zhu W
    Int J Oncol; 2024 Aug; 65(2):. PubMed ID: 38873997
    [TBL] [Abstract][Full Text] [Related]  

  • 8. LncRNA BC200 regulates the cell proliferation and cisplatin resistance in non-small cell lung cancer via PI3K/AKT pathway.
    Gao BB; Wang SX
    Eur Rev Med Pharmacol Sci; 2019 Feb; 23(3):1093-1101. PubMed ID: 30779077
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Zoledronic Acid Enhanced the Antitumor Effect of Cisplatin on Orthotopic Osteosarcoma by ROS-PI3K/AKT Signaling and Attenuated Osteolysis.
    Liu L; Geng H; Mei C; Chen L
    Oxid Med Cell Longev; 2021; 2021():6661534. PubMed ID: 33859780
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effect of microRNA-135a on Cell Proliferation, Migration, Invasion, Apoptosis and Tumor Angiogenesis Through the IGF-1/PI3K/Akt Signaling Pathway in Non-Small Cell Lung Cancer.
    Zhou Y; Li S; Li J; Wang D; Li Q
    Cell Physiol Biochem; 2017; 42(4):1431-1446. PubMed ID: 28715819
    [TBL] [Abstract][Full Text] [Related]  

  • 11. FAM83D promotes epithelial-mesenchymal transition, invasion and cisplatin resistance through regulating the AKT/mTOR pathway in non-small-cell lung cancer.
    Yin C; Lin X; Wang Y; Liu X; Xiao Y; Liu J; Snijders AM; Wei G; Mao JH; Zhang P
    Cell Oncol (Dordr); 2020 Jun; 43(3):395-407. PubMed ID: 32006253
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Inhibition of PI3K/Akt/mTOR signaling pathway alleviates ovarian cancer chemoresistance through reversing epithelial-mesenchymal transition and decreasing cancer stem cell marker expression.
    Deng J; Bai X; Feng X; Ni J; Beretov J; Graham P; Li Y
    BMC Cancer; 2019 Jun; 19(1):618. PubMed ID: 31234823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A novel herbal formula induces cell cycle arrest and apoptosis in association with suppressing the PI3K/AKT pathway in human lung cancer A549 cells.
    Xiong F; Jiang M; Huang Z; Chen M; Chen K; Zhou J; Yin L; Tang Y; Wang M; Ye L; Zhan Z; Duan J; Fu H; Zhang X
    Integr Cancer Ther; 2014 Mar; 13(2):152-60. PubMed ID: 24105357
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inhibition of PDGFR by CP-673451 induces apoptosis and increases cisplatin cytotoxicity in NSCLC cells via inhibiting the Nrf2-mediated defense mechanism.
    Yang Y; Deng Y; Chen X; Zhang J; Chen Y; Li H; Wu Q; Yang Z; Zhang L; Liu B
    Toxicol Lett; 2018 Oct; 295():88-98. PubMed ID: 29857117
    [TBL] [Abstract][Full Text] [Related]  

  • 15. (+)-Usnic Acid Induces ROS-dependent Apoptosis via Inhibition of Mitochondria Respiratory Chain Complexes and Nrf2 Expression in Lung Squamous Cell Carcinoma.
    Qi W; Lu C; Huang H; Zhang W; Song S; Liu B
    Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32013250
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Davanone terpenoid inhibits cisplatin-resistant acute myeloid leukemia cancer cell growth by inducing caspase-dependent apoptosis, loss of mitochondrial membrane potential, inhibition of cell migration and invasion and targeting PI3K/AKT/MAPK signalling pathway.
    Xiao Y; Deng T; Wang D
    J BUON; 2020; 25(3):1607-1613. PubMed ID: 32862611
    [TBL] [Abstract][Full Text] [Related]  

  • 17. SIRT6 through PI3K/Akt/mTOR signaling pathway to enhance radiosensitivity of non-Small cell lung cancer and inhibit tumor progression.
    Xiong L; Tan B; Lei X; Zhang B; Li W; Liu D; Xia T
    IUBMB Life; 2021 Sep; 73(9):1092-1102. PubMed ID: 34033225
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Propofol and Sevoflurane Alleviate Malignant Biological Behavior and Cisplatin Resistance of Xuanwei Lung Adenocarcinoma by Modulating the Wnt/β-catenin Pathway and PI3K/AKT Pathway.
    Quan Y; Li S; Wang Y; Liu G; Lv Z; Wang Z
    Anticancer Agents Med Chem; 2022; 22(11):2098-2108. PubMed ID: 35152870
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Effect of PI3K/AKT pathway on cisplatin resistance in non-small cell lung cancer].
    Zhang Y; Lu H; Xu G
    Zhongguo Fei Ai Za Zhi; 2014 Aug; 17(8):635-42. PubMed ID: 25130971
    [TBL] [Abstract][Full Text] [Related]  

  • 20. SNHG7 mediates cisplatin-resistance in non-small cell lung cancer by activating PI3K/AKT pathway.
    Chen K; Abuduwufuer A; Zhang H; Luo L; Suotesiyali M; Zou Y
    Eur Rev Med Pharmacol Sci; 2019 Aug; 23(16):6935-6943. PubMed ID: 31486493
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.